View Older Stories View More Recent Stories

May 3, 2021 09:11AM Bristol Myers Squibb Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at Upcoming American College of Cardiology’s 70th Annual Scientific Session
Apr 30, 2021 07:10AM Bristol-Myers Squibb (BMY) Announces FDA Accepts for Priority Review of Application for Opdivo as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
Apr 30, 2021 06:59AM U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
Apr 29, 2021 06:59AM Bristol Myers Squibb Reports First Quarter Financial Results for 2021
Apr 28, 2021 06:59AM Bristol Myers Squibb to Take Part in the 7th Annual Truist Life Sciences Summit
Apr 23, 2021 10:01AM Bristol-Myers Squibb (BMY) Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla
Apr 23, 2021 10:00AM Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)
Apr 23, 2021 06:53AM Bristol-Myers Squibb (BMY) Granted Positive CHMP Opinion for Onureg (azacitidine tablets; CC-486) as Maintenance Therapy for Adults with AML
Apr 23, 2021 06:51AM Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg® (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission
Apr 23, 2021 06:47AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion Recommending Approval for Opdivo Plus Yervoy as First-Line Treatment for Unresectable MPM
Apr 23, 2021 06:45AM Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
Apr 16, 2021 01:12PM Bristol-Myers Squibb (BMY) Announces FDA Approval of Opdivo Combo for dvanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma
Apr 16, 2021 01:10PM U.S. Food and Drug Administration Approves Opdivo® (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophage
Apr 14, 2021 04:20PM Bristol-Myers Squibb (BMY) Receives EC Approval for Opdivo in Combination with Cabometyx as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
Apr 14, 2021 04:16PM Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcino
Apr 13, 2021 02:00AM Evotec Launches 'BeLAB2122', Translating Academic Innovation from Leading German Life Science Region in Collaboration with Bristol Myers Squibb
Apr 10, 2021 08:30AM Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
Apr 8, 2021 07:00AM Bristol-Myers Squibb (BMY) Announces Opdivo plus Chemotherapy and Opdivo plus Yervoy Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic ESCC
Apr 8, 2021 06:59AM  CORRECTING and REPLACING Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unr
Apr 8, 2021 06:59AM Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metas
Mar 30, 2021 06:59AM Bristol Myers Squibb to Host Virtual Investor Event to Discuss AAD VMX Highlights
Mar 29, 2021 06:59AM Bristol-Myers Squibb (BMY) Announces EMA Validates its Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
Mar 29, 2021 06:59AM European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
Mar 29, 2021 06:29AM Bristol-Myers Squibb (BMY), bluebird bio (BLUE) Announces FDA Approval for Abecma for Relapsed or Refractory Multiple Myeloma
Mar 26, 2021 10:59PM U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Mye
Mar 25, 2021 07:00AM Bristol-Myers Squibb (BMY) Announces RELATIVITY-047 Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary
Mar 25, 2021 06:59AM Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets
Mar 19, 2021 07:00AM Bristol-Myers Squibb (BMY) Announces FDA Accepts its Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Mar 19, 2021 06:59AM U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb’s Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Mar 11, 2021 06:59AM Bristol Myers Squibb to Report Results for First Quarter 2021 on April 29, 2021
Mar 2, 2021 06:59AM Bristol Myers Squibb to Participate in Barclays Virtual Global Healthcare Conference
Mar 1, 2021 04:16PM Bristol Myers Squibb Announces Dividend
Feb 26, 2021 06:26AM Bristol Myers Squibb (BMY) Receives Positive CHMP Opinion for Opdivo in Combination with Cabometyx as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
Feb 26, 2021 06:25AM Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
Feb 25, 2021 01:00AM Press release Biocartis Group NV: BIOCARTIS ANNOUNCES 2020 RESULTS AND 2021 OUTLOOK
Feb 24, 2021 07:10AM Bristol Myers Squibb to Take Part in the Cowen Virtual 41st Annual Health Care Conference
Feb 24, 2021 06:59AM Bristol Myers Squibb Donates $11 Million to Advance Health Equity
Feb 23, 2021 09:00AM Bristol Myers Squibb and the American Music Therapy Association Team Up with Ben Platt and Sister-in-Law Courtney Platt to Launch MS in Harmony, a First-of-its-Kind Music Therapy Offering for People L
Feb 23, 2021 06:59AM Bristol Myers Squibb to Participate in Raymond James Virtual 42nd Annual Institutional Investors Conference
Feb 22, 2021 06:15PM Bristol Myers Squibb and Celgene Issue Notices of Redemption and Partial Redemption of Certain of Their Senior Notes at “Make Whole” Prices
Feb 19, 2021 05:04PM Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
Feb 18, 2021 09:29PM Bristol Myers Squibb Announces Early Participation Results and Early Settlement of Tender Offers for Up to an Aggregate Purchase Price of Up to $4.0 Billion
Feb 16, 2021 07:38AM Bristol Myers Squibb Canada (BMY), Acceleron Pharma (XLRN) Announce Health Canada Approves REBLOZYL, New Class of Treatment for Adult Patients Living With Myelodysplastic Syndromes
Feb 8, 2021 05:00PM Adjuvant Treatment with Opdivo (nivolumab) Demonstrates Statistically Significant and Clinically Meaningful Improvement in Disease-Free Survival in Patients with Muscle-Invasive Urothelial Carcinoma i
Feb 8, 2021 05:00PM OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma in the P
Feb 8, 2021 12:30PM Bristol-Myers Squibb (BMY) Granted EC Approval for Inrebic (fedratinib) for Adult Patients with Newly Diagnosed & Previously Treated Myelofibrosis
Feb 8, 2021 12:12PM Bristol Myers Squibb Receives European Commission Approval for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
Feb 5, 2021 04:39PM U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma
Feb 5, 2021 06:59AM Bristol Myers Squibb to Participate in Guggenheim’s Virtual Healthcare Talks | 2021 Oncology Day
Feb 4, 2021 06:59AM Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020
View More Recent Stories View Older Stories